Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
Related Questions
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
How frequently do you recommend skin cancer screens in your patients with kidney transplants who are on immunosuppression?
What chemoprophylaxis, if any, would you consider in a transplant patient with numerous KC/NMSCs?
Would you offer adjuvant immunotherapy in an elderly patient with stage IIB desmoplastic melanoma post resection with underlying autoimmune disease?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
How would you manage a scalp squamous cell carcinoma s/p Mohs with high risk features who underwent placental grafting to expedite the healing process?
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
